NCT01901159已完成1 期
A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
- 主要终点
- Bioavailability: Plasma concentration of RO4995819
研究概览
简要总结
This randomized, open-label, cross-over study will assess the bioavailability and safety of RO4995819 in healthy volunteers. Volunteers will receive two different formulations (tablet and capsule) of the study drug under fed and fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy non-smoking male and female volunteers, 18 to 65 years of age, inclusive.
- •A body mass index (BMI) between 18 to 30 kg/m2, inclusive.
- •Able to participate and willing to give written informed consent and to comply with the study restrictions.
- •Willing not to participate in any other clinical trial with an investigational drug or device for at least 3 months following the follow up visit.
- •Male volunteers and their partners of childbearing potential must use two adequate methods of contraception. Female volunteers who are not either surgically sterile or postmenopausal must commit to use two adequate methods of contraception throughout the study and until at least 5 months after last dosing.
排除标准
- •History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder or cancer
- •Significant past or present disorders of the central nervous system, psychiatric disorders, behavioral disturbances
- •Diseases or medical conditions that are capable of altering the absorption, metabolism or elimination of drugs
- •Any condition or disease detected during the medical interview / physical examination that would render the volunteer unsuitable for the study, place the volunteer at undue risk or interfere with the ability of the volunteer to complete the study in the opinion of the Investigator
- •Clinically significant abnormalities in laboratory test results
- •Confirmed resting pulse rate greater than 90 or less than 40 beats per minute (bpm) at screening
- •Confirmed systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg at screening
- •Any major illness within the 4 weeks prior to dosing or any acute disease state within 7 days of study start
- •Any confirmed allergic reaction against any drug or multiple allergies
- •Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse
- •Infection with hepatitis B, hepatitis C virus, or HIV 1 and HIV 2
研究组 & 干预措施
RO4995819 capsule
Experimental
干预措施: RO4995819 (Drug)
RO4995819 tablet
Experimental
干预措施: RO4995819 (Drug)
结局指标
主要结局
Bioavailability: Plasma concentration of RO4995819
时间窗: Approximately 3 months
次要结局
- Safety: incidence of adverse events(Approximately 3 months)
研究者
相似试验
已完成
1 期
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid TumoursBreast Cancer, Colorectal CancerNCT01493336Hoffmann-La Roche37
已完成
1 期
Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin TabletsPainNCT03056703Bayer38
已完成
1 期
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy VolunteersAcute Coronary SyndromeNCT03671941Chong Kun Dang Pharmaceutical31
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy SubjectsHealth, SubjectiveNCT04087525Hanmi Pharmaceutical Company Limited31
Unknown
1 期
A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.HealthyNCT05506007Dong-A ST Co., Ltd.88